Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin + rosiglitazone
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
The combination of insulin and rosiglitazone is **not recommended** for clinical use due to increased risk of heart failure. Rosiglitazone is an oral antidiabetic agent that acts primarily by increasing insulin sensitivity, while insulin is a hormone that helps control blood glucose levels. Studies have shown that this combination results in a higher rate of congestive heart failure.
02
Targets
SIK2 (Salt inducible kinase 2)INSR (Insulin receptor)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on insulin + rosiglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin + rosiglitazone.